Aptinyx

54 articles with Aptinyx

• Aptinyx Promotes David Houck to Chief Development Officer

  5/3/2018

  Aptinyx Inc., a clinical-stage biopharmaceutical company developing transformative therapies for challenging neurologic disorders, today announced that David R. Houck, Ph.D. has been promoted to chief development officer.

• Aptinyx Presents Data on NMDA Receptor Modulator NYX-458 in a Preclinical Model of Parkinson's Cognitive Impairment at the AAT-AD/PD Focus Meeting 2018

  3/15/2018

  Aptinyx Inc. announced the presentation of preclinical data that supports advancing the development of a novel N-methyl D-aspartate (NMDA) receptor modulator, NYX-458, as a treatment for cognitive impairment associated with Parkinson's disease.

• Aptinyx Presents Preclinical and Phase 1 Clinical Data from NYX-2925 at the 20th Annual Meeting of the American Society for Experimental Neurotherapeutics

  3/8/2018

  Aptinyx Inc. announced they will present preclinical and early-stage clinical data from studies of the company's lead product candidate, NYX-2925, at the 20th Annual Meeting of the American Society for Experimental Neurotherapeutics, March 7-10, 2018 in Rockville, MD.

• Aptinyx Presents NYX-2925 Preclinical Data in Chemotherapy-induced Neuropathic Pain at the American Pain Society Annual Scientific Meeting

  3/6/2018

  Aptinyx Inc., a clinical-stage biopharmaceutical company developing transformative therapies for challenging neurologic disorders, today announced their presentation at the American Pain Society's Annual Scientific Meeting, March 4-6, 2018 in Anaheim, CA.

• Aptinyx Appoints Ashish Khanna CFO and CBO

  2/13/2018

  Mr. Khanna has served as chief business officer of Aptinyx since the company's inception in 2015.

• 

  Aptinyx Bags $70M Financing to Fuel Expanding Pipeline

  12/18/2017

  The round was led by Bain Capital Life Sciences.

• Aptinyx Granted Fast Track Designation, Initiates Phase I for Second Clinical Candidate, NYX-783, in Post-Traumatic Stress Disorder

  12/7/2017

  The U.S. Food and Drug Administration has granted Aptinyx Fast Track designation for the development of NYX-783 for the treatment of PTSD.

• Aptinyx Bolsters Executive Leadership Team With Appointment of Andy Kidd as CCO

  12/7/2017

  Andy's experience will be instrumental in achieving and leveraging anticipated milestones,.

• Aptinyx Initiates Phase II Clinical Studies Evaluating NYX-2925 In Two Chronic Pain Conditions

  8/1/2017

• Aptinyx Chief Scientific Officer Joseph Moskal, Ph.D. Named Fellow By National Academy Of Inventors And The American Institute For Medical And Biological Engineering

  2/21/2017

• Aptinyx Awarded Up To $2.85 Million In NIH Grants To Research NMDA Receptor Modulation For The Treatment Of Neuropathic Pain And Age-Related Cognitive Decline

  11/11/2016

• Aptinyx Receives FDA Fast Track Designation For Development Of NYX-2925 As Treatment For Neuropathic Pain Associated With Diabetic Peripheral Neuropathy

  9/13/2016

• Aptinyx Initiates Dosing In Phase 1 Clinical Study Of Lead NMDA-Receptor Modulator, NYX-2925

  7/13/2016

• Naurex Spinout Aptinyx Banks $65 Million Series A to Advance Therapies for Neurological Disorders

  5/10/2016